vs
Electromed, Inc.（ELMD）とLivaNova PLC（LIVN）の財務データ比較。上の社名をクリックして会社を切り替えられます
LivaNova PLCの直近四半期売上が大きい（$360.9M vs $18.9M、Electromed, Inc.の約19.1倍）。Electromed, Inc.の純利益率が高く（14.6% vs 8.6%、差は6.0%）。Electromed, Inc.の前年同期比売上増加率が高い（16.3% vs 12.1%）。LivaNova PLCの直近四半期フリーキャッシュフローが多い（$50.2M vs $2.4M）。過去8四半期でElectromed, Inc.の売上複合成長率が高い（16.7% vs 10.6%）
エレクトロメッド社は呼吸器ケア機器の開発・製造・販売を事業とする医療機器企業で、主力製品は高頻度胸壁振動を利用した痰排出システムです。主に米国の在宅ケア事業者や医療機関向けに製品を供給し、嚢胞性線維症やCOPDなどの呼吸器疾患患者の気道ケアを支援しています。
LivaNova PLCは医療機器メーカーで、イギリスに本社を置いています。心臓外科手術用機器と神経調整用機器の開発を主な事業とし、2015年に米国のサイバロニクス社とイタリアのソリン社が27億米ドルで合併して設立されました。現在はNASDAQに上場し、証券コードはLIVNです。
ELMD vs LIVN — 直接比較
損益計算書 — Q2 2026 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $18.9M | $360.9M |
| 純利益 | $2.8M | $30.9M |
| 粗利率 | 78.4% | 65.2% |
| 営業利益率 | 19.2% | 11.8% |
| 純利益率 | 14.6% | 8.6% |
| 売上前年比 | 16.3% | 12.1% |
| 純利益前年比 | 40.3% | -44.7% |
| EPS（希薄化後） | $0.32 | $0.57 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $18.9M | $360.9M | ||
| Q3 25 | $16.9M | $357.8M | ||
| Q2 25 | $17.4M | $352.5M | ||
| Q1 25 | $15.7M | $316.9M | ||
| Q4 24 | $16.3M | $321.8M | ||
| Q3 24 | $14.7M | $318.1M | ||
| Q2 24 | $14.8M | $318.6M | ||
| Q1 24 | $13.9M | $294.9M |
| Q4 25 | $2.8M | $30.9M | ||
| Q3 25 | $2.1M | $26.8M | ||
| Q2 25 | $2.2M | $27.2M | ||
| Q1 25 | $1.9M | $-327.3M | ||
| Q4 24 | $2.0M | $55.9M | ||
| Q3 24 | $1.5M | $33.0M | ||
| Q2 24 | $1.8M | $16.3M | ||
| Q1 24 | $1.5M | $-41.9M |
| Q4 25 | 78.4% | 65.2% | ||
| Q3 25 | 78.1% | 68.4% | ||
| Q2 25 | 78.3% | 67.8% | ||
| Q1 25 | 78.0% | 69.7% | ||
| Q4 24 | 77.7% | 68.2% | ||
| Q3 24 | 78.3% | 70.8% | ||
| Q2 24 | 76.2% | 68.7% | ||
| Q1 24 | 74.8% | 70.3% |
| Q4 25 | 19.2% | 11.8% | ||
| Q3 25 | 15.8% | 15.1% | ||
| Q2 25 | 17.5% | 15.4% | ||
| Q1 25 | 13.6% | 15.3% | ||
| Q4 24 | 15.6% | 11.5% | ||
| Q3 24 | 13.2% | 11.2% | ||
| Q2 24 | 15.7% | 12.6% | ||
| Q1 24 | 13.3% | 5.5% |
| Q4 25 | 14.6% | 8.6% | ||
| Q3 25 | 12.6% | 7.5% | ||
| Q2 25 | 12.7% | 7.7% | ||
| Q1 25 | 12.1% | -103.3% | ||
| Q4 24 | 12.1% | 17.4% | ||
| Q3 24 | 10.0% | 10.4% | ||
| Q2 24 | 12.3% | 5.1% | ||
| Q1 24 | 10.8% | -14.2% |
| Q4 25 | $0.32 | $0.57 | ||
| Q3 25 | $0.25 | $0.49 | ||
| Q2 25 | $0.26 | $0.50 | ||
| Q1 25 | $0.21 | $-6.01 | ||
| Q4 24 | $0.22 | $1.04 | ||
| Q3 24 | $0.16 | $0.60 | ||
| Q2 24 | $0.20 | $0.30 | ||
| Q1 24 | $0.17 | $-0.78 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $13.8M | $635.6M |
| 総負債低いほど良い | — | $376.1M |
| 株主資本純資産 | $45.4M | $1.2B |
| 総資産 | $54.9M | $2.6B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.31× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $13.8M | $635.6M | ||
| Q3 25 | $14.1M | $646.1M | ||
| Q2 25 | $15.3M | $593.6M | ||
| Q1 25 | $15.2M | $738.4M | ||
| Q4 24 | $16.2M | $428.9M | ||
| Q3 24 | $13.9M | $346.4M | ||
| Q2 24 | $16.1M | $329.2M | ||
| Q1 24 | $11.7M | $309.2M |
| Q4 25 | — | $376.1M | ||
| Q3 25 | — | $434.5M | ||
| Q2 25 | — | $430.6M | ||
| Q1 25 | — | $628.2M | ||
| Q4 24 | — | $627.0M | ||
| Q3 24 | — | $625.5M | ||
| Q2 24 | — | $624.5M | ||
| Q1 24 | — | $623.8M |
| Q4 25 | $45.4M | $1.2B | ||
| Q3 25 | $44.7M | $1.2B | ||
| Q2 25 | $43.2M | $1.1B | ||
| Q1 25 | $43.9M | $1.0B | ||
| Q4 24 | $43.6M | $1.3B | ||
| Q3 24 | $41.5M | $1.3B | ||
| Q2 24 | $44.5M | $1.2B | ||
| Q1 24 | $42.5M | $1.2B |
| Q4 25 | $54.9M | $2.6B | ||
| Q3 25 | $53.6M | $2.6B | ||
| Q2 25 | $53.8M | $2.5B | ||
| Q1 25 | $52.5M | $2.6B | ||
| Q4 24 | $52.3M | $2.5B | ||
| Q3 24 | $48.9M | $2.5B | ||
| Q2 24 | $52.2M | $2.5B | ||
| Q1 24 | $48.9M | $2.5B |
| Q4 25 | — | 0.31× | ||
| Q3 25 | — | 0.38× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 0.61× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.51× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $3.0M | $82.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $2.4M | $50.2M |
| FCFマージンFCF / 売上 | 12.7% | 13.9% |
| 設備投資強度設備投資 / 売上 | 3.4% | 8.9% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 2.67× |
| 直近12ヶ月FCF直近4四半期 | $7.9M | $173.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $3.0M | $82.4M | ||
| Q3 25 | $169.0K | $85.1M | ||
| Q2 25 | $3.9M | $62.9M | ||
| Q1 25 | $2.1M | $24.0M | ||
| Q4 24 | $3.2M | $78.7M | ||
| Q3 24 | $2.3M | $51.0M | ||
| Q2 24 | $4.5M | $43.4M | ||
| Q1 24 | $1.4M | $10.0M |
| Q4 25 | $2.4M | $50.2M | ||
| Q3 25 | $-83.0K | $62.2M | ||
| Q2 25 | $3.7M | $47.8M | ||
| Q1 25 | $1.9M | $13.2M | ||
| Q4 24 | $2.9M | $68.3M | ||
| Q3 24 | $2.3M | $32.8M | ||
| Q2 24 | $4.5M | $31.2M | ||
| Q1 24 | $1.3M | $3.6M |
| Q4 25 | 12.7% | 13.9% | ||
| Q3 25 | -0.5% | 17.4% | ||
| Q2 25 | 21.4% | 13.6% | ||
| Q1 25 | 12.2% | 4.2% | ||
| Q4 24 | 18.0% | 21.2% | ||
| Q3 24 | 15.5% | 10.3% | ||
| Q2 24 | 30.1% | 9.8% | ||
| Q1 24 | 9.1% | 1.2% |
| Q4 25 | 3.4% | 8.9% | ||
| Q3 25 | 1.5% | 6.4% | ||
| Q2 25 | 0.8% | 4.3% | ||
| Q1 25 | 1.0% | 3.4% | ||
| Q4 24 | 1.4% | 3.2% | ||
| Q3 24 | 0.3% | 5.7% | ||
| Q2 24 | 0.1% | 3.8% | ||
| Q1 24 | 0.6% | 2.2% |
| Q4 25 | 1.10× | 2.67× | ||
| Q3 25 | 0.08× | 3.18× | ||
| Q2 25 | 1.75× | 2.32× | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.60× | 1.41× | ||
| Q3 24 | 1.57× | 1.55× | ||
| Q2 24 | 2.46× | 2.65× | ||
| Q1 24 | 0.90× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ELMD
セグメントデータなし
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
